NVCT
Nuvectis Pharma, Inc. Health Care Pharmaceutical Preparations Russell 3000
$18.48Close
$474.5MMarket cap
$5.65 – $28.5352-week range
Nov 3, 2026Next report
Highlights
Strengths
- Leading the market RS 97 · stronger than 97% of stocks over 12 months
Cautions
- Trend not confirmed 6 of 8 conditions · under the 50-day, over 25% off the high
- Far from its high 35% below its 52-week high
- Results soon Nov 3, 2026, in 2 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
35%
1wk
down 7.8%
price change
1mo
down 12.5%
price change
12-month return
up 178%
market up 11% ·
its own up 162%
F-score
—
— Not assessed
Altman Z
—
Unknown
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
25.8×
price / book
Earnings yield
down 6.2%
EBIT / enterprise value
Cheaper than
—
of the market · not assessed
Revenue growth
—
year on year
EPS growth
—
latest quarter
Sales growth
—
latest quarter
ROE
down 188%
return on equity
Free cash margin
—
-$16.0M FCF
D/E
—
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Trade setup
ATR%
7.3%
$1.35 a day · 2×ATR $15.78
RS
97 / 99
vs the universe
Trend
6 / 8
under the 50-day, over 25% off the high
Relative volume
0.9×
vs 50-day average
Up/down volume
1.00
50 sessions
Implied move
—
no option chain · report Nov 3, 2026
Trend template · 6 of 8
- Price above the 50-day average: fails
- Within 25% of the 52-week high: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- Shareholders diluted The share count rose 31.7% over the year, from 19m to 26m shares. Each existing share owns a smaller fraction of the company than it did a year ago.
Last reported
Aug 4, 2026
Results reaction
Aug 4, 2026-12% vs market2 sessions after results
Financials
- Cash
- Long-term debt
| FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|
| Operating income | -$12.9M | -$19.2M | -$22.9M | -$19.8M | -$27.6M |
| Net income | -$12.9M | -$19.1M | -$22.3M | -$19.0M | -$26.4M |
| Earnings per share | -$3.02 | -$1.51 | -$1.43 | -$1.11 | -$1.21 |
| Free cash flow | -$9.5M | -$13.6M | -$16.0M | -$12.2M | -$16.0M |
| Cash | $5.7M | $20.0M | $19.1M | $18.5M | $31.6M |
| Shareholders' equity | -$11.0M | $14.2M | $12.2M | $9.7M | $18.4M |
| Shares outstanding | 4.51m | 15.19m | 17.42m | 19.50m | 25.68m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Aug 4, 2026 | Quarterly ↗ | Jun 30, 2026 | 35d |
| May 5, 2026 | Quarterly ↗ | Mar 31, 2026 | 35d |
| Feb 11, 2026 | Annual ↗ | Dec 31, 2025 | 42d |
| Nov 4, 2025 | Quarterly ↗ | Sep 30, 2025 | 35d |
| Aug 5, 2025 | Quarterly ↗ | Jun 30, 2025 | 36d |
| May 6, 2025 | Quarterly ↗ | Mar 31, 2025 | 36d |
| Feb 25, 2025 | Annual ↗ | Dec 31, 2024 | 56d |
| Nov 5, 2024 | Quarterly ↗ | Sep 30, 2024 | 36d |
| Aug 6, 2024 | Quarterly ↗ | Jun 30, 2024 | 37d |
| May 7, 2024 | Quarterly ↗ | Mar 31, 2024 | 37d |
| Mar 5, 2024 | Annual ↗ | Dec 31, 2023 | 65d |
| Nov 8, 2023 | Quarterly ↗ | Sep 30, 2023 | 39d |
Current reports
| Filed | Disclosed |
|---|---|
| Aug 21, 2026 | Other events ↗ |
| Aug 4, 2026 | Results ↗ |
| Jun 30, 2026 | Material agreement · Other events ↗ |
| Jun 29, 2026 | Other events ↗ |
| Jun 23, 2026 | Material agreement · Other events ↗ |
| Jun 12, 2026 | Shareholder vote ↗ |
| May 5, 2026 | Results ↗ |
| Feb 11, 2026 | Results ↗ |
| Nov 4, 2025 | Results ↗ |
| Sep 25, 2025 | Director or officer change ↗ |
| Aug 5, 2025 | Results ↗ |
| Jun 13, 2025 | Shareholder vote ↗ |